Skip to main content

MRI Susceptibility-Weighted Imaging (SWI)

By Troy Zhou, PhD, DABR, DABSNM
• 16 min read

Susceptibility-weighted imaging turns a part of the MRI signal that most sequences throw away — the phase — into diagnostic contrast. By combining the magnitude and phase of a high-resolution, flow-compensated 3D gradient-echo acquisition, SWI makes veins, small hemorrhages, iron, and calcium conspicuous in a way no single conventional sequence can match 1, 2.

Most clinical MRI reconstructs only the magnitude of the complex signal. But every gradient-echo voxel also carries a phase, and that phase encodes the local magnetic field — which is perturbed wherever a substance has a magnetic susceptibility different from its surroundings. Deoxygenated venous blood, the iron in ferritin and hemosiderin, and the calcium in a calcification all shift the local field, and therefore the phase. SWI is the technique that harvests that phase and folds it back into the image 1.

This guide explains the phase physics behind SWI, how the phase mask is built and applied, why field strength and echo time are coupled, the clinical contrast SWI produces, and the quality control that keeps it reliable. DRPS supports MRI programs through its MRI physics testing and accreditation support services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Introduction

A gradient-echo MRI signal is a complex number with a magnitude and a phase. The magnitude is what radiologists usually look at. The phase reports how fast spins in a voxel precessed relative to a reference — and precession frequency depends on the local magnetic field. Where a paramagnetic or diamagnetic substance distorts the field, spins there accumulate extra phase. Over a long enough echo time, that extra phase becomes measurable 1.

SWI was introduced by Haacke and colleagues as a way to exploit this phase systematically 1. Rather than display phase on its own, SWI uses it to build a mask that darkens voxels with susceptibility-induced phase shifts, then multiplies that mask into the magnitude image. The result keeps the familiar anatomy of the magnitude image but dramatically amplifies the contrast of small susceptibility sources — most strikingly the cerebral veins, which carry deoxygenated blood 1, 2.

Because of this sensitivity, SWI has become a standard part of many brain MRI protocols, used to detect microbleeds, map venous anatomy, characterize hemorrhage and calcification, and study iron deposition in neurodegeneration 3, 4. It is also the conceptual parent of quantitative susceptibility mapping (QSM), which turns the same phase data into a quantitative tissue property 4, 5.

Topic Explanation

Phase, field, and susceptibility

The core physics of SWI is a single proportionality. A voxel whose local field is offset by from the reference accumulates, over echo time , a phase:

where is the gyromagnetic ratio ( for protons). The field offset itself is produced by the difference in magnetic susceptibility between a structure and its surroundings, and it scales with the main field . Two consequences follow immediately and drive the whole technique 1, 2:

  • Phase grows with echo time. A longer TE lets more susceptibility phase accumulate — until it is so long that signal decays and phase wraps. SWI uses a TE long enough to develop venous phase but short enough to preserve signal.
  • Phase grows with field strength. Because , the same phase contrast develops at a shorter TE as field strength rises.

Building the SWI image

The SWI reconstruction follows a defined sequence of steps 1, 2:

  1. Acquire a 3D, fully flow-compensated, high-resolution gradient-echo dataset, keeping both magnitude and phase.
  2. High-pass filter the phase image to remove slowly varying background field effects (from large-scale shim imperfections and air–tissue interfaces), leaving the local susceptibility phase.
  3. Create a phase mask that ranges from zero to one, assigning the strongest suppression to voxels with the target phase sign.
  4. Multiply the mask into the magnitude image several times. Haacke's analysis showed that multiplying the mask approximately four times maximizes the contrast-to-noise ratio for venous structures 1.
  5. Project with a minimum intensity projection (mIP) over several contiguous slices so that the dark, low-signal veins and microbleeds connect into continuous structures 4.

Schematically, the processed image is the magnitude scaled by the mask raised to a small integer power :

Paramagnetic versus diamagnetic

Susceptibility has a sign. Paramagnetic substances — deoxyhemoglobin, ferritin, and hemosiderin — increase the local field and shift phase one way. Diamagnetic substances — notably calcium — decrease it and shift phase the other way. On a correctly interpreted filtered phase image, calcium and blood products therefore appear with opposite signs, which is the basis for using SWI phase to distinguish a calcification from a small hemorrhage when the magnitude image alone cannot 4, 5.

Key Technical Principles

Echo time and field strength are coupled

Because susceptibility phase is proportional to the product , the recommended echo time falls as field strength rises. Representative starting parameters from the technique's originators pair a longer TE at 1.5T with a roughly halved TE at 3T, as summarized below 2. These are representative recommended values and should be confirmed against the scanner, software version, and clinical protocol.

Parameter 1.5T (representative) 3T (representative) Why it changes
Echo time (TE) ~40 ms ~20 ms Phase ∝ B₀·TE, so TE halves as field doubles
Flip angle ~20° ~15° Lower angle limits T1 saturation and SAR at higher field
Acquisition 3D flow-compensated gradient echo 3D flow-compensated gradient echo Phase fidelity needs flow compensation and thin slices
Phase-mask multiplications ~4 ~4 Near-optimal CNR for veins

Worked example — scaling TE with field. Suppose a 1.5T protocol uses to develop venous phase. Because the susceptibility phase scales as , holding the accumulated phase constant when moving to 3T requires:

which is why 3T SWI protocols use roughly half the echo time of 1.5T protocols for comparable venous contrast 2. Shorter TE at higher field is also advantageous because it leaves less time for signal dephasing near air–tissue interfaces, though those interface artifacts still grow with field strength and must be managed.

The cost of sensitivity: artifacts

The same field sensitivity that makes SWI powerful also makes it vulnerable. Air–tissue boundaries (sinuses, skull base, mastoids) create large background fields that can overwhelm local contrast; aggressive high-pass filtering removes genuine signal along with background; motion corrupts phase; and metal produces severe blooming. SWI quality therefore depends directly on field homogeneity and shimming, which is why the technique is sensitive to the same B0 quality a physicist monitors in routine QC. For the underlying field and artifact checks, see MRI B0 homogeneity and center-frequency QC and MRI image artifacts QC.

From SWI to QSM

SWI is a weighted image: the phase mask amplifies contrast but does not yield a number. Quantitative susceptibility mapping (QSM) goes further, solving the inverse problem that relates the measured field map to the underlying susceptibility distribution and producing a map in parts per million 4, 5. QSM removes some SWI ambiguities — notably the blooming and orientation dependence of phase — and allows susceptibility (for example, brain iron) to be measured rather than merely displayed. It is more computationally demanding and still largely a research and advanced-clinical tool, but it builds on exactly the same gradient-echo phase data 5. For related quantitative mapping, see MRI relaxometry: T1 and T2 mapping QC.

Clinical Impact

Microbleeds and hemorrhage

SWI is markedly more sensitive than conventional T2*-weighted gradient echo for cerebral microbleeds. The number of microbleeds detected depends strongly on pulse sequence, spatial resolution, field strength, and post-processing — all factors SWI optimizes 6. This matters for cerebral amyloid angiopathy, hypertensive microangiopathy, and anticoagulation decisions, where microbleed burden informs risk. SWI also depicts the full extent and age of hemorrhage through the paramagnetic evolution of blood products 3.

Traumatic brain injury and venous anatomy

In diffuse axonal injury, SWI reveals small hemorrhagic shear lesions that are invisible on routine sequences, improving characterization of injury severity. Its minimum intensity projections map the cerebral venous architecture in detail, aiding the diagnosis of developmental venous anomalies, thrombosis, and vascular malformations such as cavernomas 3, 4.

Neurodegeneration and iron

Because SWI and QSM are sensitive to tissue iron, they are used to study iron deposition in the basal ganglia and its changes in neurodegenerative disease. Quantitative susceptibility, in particular, provides a reproducible biomarker of iron content that magnitude imaging cannot 4, 5.

Practical Optimization Tips

1. Keep SWI parameters constant

Phase contrast depends on TE, resolution, and filtering. For any comparison across time or across patients, hold the SWI protocol fixed; a changed TE changes the contrast.

2. Match TE to field strength

Use the shorter echo time appropriate to 3T and the longer one to 1.5T. Do not transplant a 1.5T TE onto a 3T scanner or venous contrast and artifact balance will be wrong 2.

3. Shim well and compensate flow

SWI is only as good as the field it is acquired in. Verify shimming and ensure full flow compensation; both are prerequisites for clean phase. This ties directly to routine B0 and center-frequency QC.

4. Read the phase, not just the SWI

When distinguishing calcium from hemorrhage, inspect the filtered phase image and know the scanner's handedness convention. The sign of the phase shift carries the diagnostic information.

5. Interpret mIP thickness deliberately

A thicker minimum intensity projection connects more venous anatomy but can bury a solitary microbleed in a vessel. Use a projection thickness suited to the clinical question.

Common pitfalls to avoid

  • Transplanting echo times between field strengths. TE must scale inversely with B0.
  • Over-filtering the phase. Aggressive high-pass filtering erases real local susceptibility along with background field.
  • Ignoring handedness. The paramagnetic/diamagnetic phase sign depends on the system convention; misreading it inverts the calcium-versus-blood call.
  • Changing parameters between serial scans. Comparability of microbleed counts requires fixed technique.
  • Treating SWI as quantitative. SWI is weighted, not measured; use QSM when a number is needed.

Regulatory Considerations

SWI is an MRI technique, so it falls under MRI accreditation, equipment performance monitoring, and MR safety rather than any ionizing-radiation rule. There is no radiation dose in MRI, but the images still have to meet image-quality standards, and the scanner must be operated under a documented MR safety program.

Key frameworks to reference:

  • ACR MRI Accreditation Program, which sets image-quality and phantom-based performance requirements that a facility must meet, and under which the MRI scanner producing SWI is accredited 7.
  • ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of MR Imaging Equipment, which defines the qualified medical physicist's role in acceptance testing and annual performance evaluation of the MRI system 8.
  • ACR Manual on MR Safety, the consensus reference for the zoned-access MR safety program, screening, and implant management that governs safe operation of the scanner 9.
  • FDA 21 CFR Part 892, under which MRI systems are regulated as medical devices, with magnetic-field and specific-absorption-rate operating limits 10.

MRI equipment is FDA-regulated as a device, and its clinical operation is governed by accreditation and MR safety requirements rather than state radioactive-material or X-ray rules. Among the states DRPS serves, MRI performance monitoring and accreditation follow these national (ACR, AAPM, FDA, Joint Commission) frameworks. DRPS supports facilities through MRI physics testing, accreditation support, and medical physics consulting.

Frequently Asked Questions (FAQs)

What is susceptibility-weighted imaging (SWI)?

SWI is an MRI technique that enhances contrast using differences in magnetic susceptibility between tissues. It combines the magnitude and the phase of a high-resolution, flow-compensated 3D gradient-echo acquisition so that substances such as deoxygenated blood, iron, and calcium, which perturb the local magnetic field, become conspicuous — most visibly veins and small hemorrhages.

How is SWI different from a standard T2*-weighted gradient echo?

A standard T2*-weighted gradient echo uses only the magnitude image. SWI additionally uses the phase image, which directly measures local field offsets caused by susceptibility. A processed phase mask is multiplied into the magnitude image to amplify susceptibility contrast, making SWI more sensitive than conventional gradient echo to small susceptibility sources such as microbleeds.

Why does SWI use a minimum intensity projection?

Veins and microbleeds appear as low-signal (dark) structures on SWI. A minimum intensity projection over several contiguous slices connects these dark structures across slices, displaying the continuous venous architecture on a single image in a way no individual slice can show.

Can SWI tell calcium from hemorrhage?

Often, yes. Paramagnetic substances such as deoxyhemoglobin and iron shift the phase in one direction, while diamagnetic calcium shifts it in the opposite direction. On the filtered phase image, calcium and blood products therefore appear with opposite signs, which can help distinguish a calcification from a small bleed when the magnitude image alone is ambiguous.

Does SWI work better at 3T than 1.5T?

Susceptibility-induced phase scales with field strength, so the same phase contrast develops at a shorter echo time at 3T than at 1.5T. Higher field strength generally improves SWI sensitivity and allows shorter echo times, though it also increases some artifacts near air–tissue interfaces, so acquisition parameters are adjusted for the field.

What is quantitative susceptibility mapping (QSM)?

QSM is a processing technique that solves the inverse problem of converting the measured phase into a map of the underlying magnetic susceptibility in parts per million. Unlike SWI, which is a weighted image, QSM provides a quantitative tissue property that can be measured and compared, for example to estimate brain iron.

What quality control does SWI need?

SWI relies on field homogeneity, correct flow compensation, stable gradients, and consistent sequence parameters, so it depends on the same routine MRI quality-control program a medical physicist runs — center-frequency and B0 shimming, signal-to-noise and geometric-distortion checks, and ACR accreditation testing — plus verification that the SWI protocol parameters are held constant across scans.

Key Takeaways

  • SWI uses phase, not just magnitude. It harvests the susceptibility-induced phase that conventional sequences discard and folds it into the image.
  • Phase scales with TE and B0. The susceptibility phase grows with both echo time and field strength, which is why 3T SWI uses roughly half the echo time of 1.5T.
  • A phase mask amplifies contrast. Multiplying the phase mask into the magnitude image about four times maximizes venous contrast-to-noise.
  • Sign distinguishes substances. Paramagnetic blood products and diamagnetic calcium shift phase in opposite directions, helping separate hemorrhage from calcification.
  • SWI is highly sensitive to microbleeds, more so than conventional gradient echo, but the count depends on sequence, resolution, field, and processing.
  • QSM makes it quantitative. The same phase data can be inverted into a susceptibility map in parts per million.

Conclusion

Susceptibility-weighted imaging is a case study in getting more from data a scanner already acquires. By treating phase as signal rather than noise, SWI reveals veins, microbleeds, iron, and calcium with a sensitivity that magnitude imaging alone cannot provide. Its power comes with dependence: on echo time matched to field strength, on clean shimming and flow compensation, and on consistent parameters across scans.

For the medical physicist, SWI is both an image-quality asset and a QC responsibility. Its reliability rests on the routine MRI performance program — field homogeneity, center frequency, signal-to-noise, geometric distortion, and accreditation testing — and on protocol discipline. Facilities that treat SWI parameters as fixed, validated settings rather than ad hoc choices will produce consistent, comparable, and defensible images.

How DRPS Can Help

Diagnostic Radiation Physics Services helps MRI facilities keep advanced sequences like SWI reliable by anchoring them to a documented performance and safety program. This can include MRI acceptance testing and annual performance evaluation, ACR accreditation support and phantom QC, B0 and center-frequency monitoring, geometric-distortion and signal-to-noise assessment, and MR safety program review.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware, through MRI physics testing, accreditation support, and medical physics consulting.

Related Resources

References

  1. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004;52(3):612-618. doi:10.1002/mrm.20198. PubMed
  2. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol. 2009;30(1):19-30. doi:10.3174/ajnr.A1400. PubMed
  3. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol. 2009;30(2):232-252. doi:10.3174/ajnr.A1461. PubMed
  4. Liu C, Li W, Tong KA, Yeom KW, Kuzminski S. Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 2015;42(1):23-41. doi:10.1002/jmri.24768. PubMed
  5. Wang Y, Liu T. Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med. 2015;73(1):82-101. doi:10.1002/mrm.25358. PubMed
  6. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8(2):165-174. doi:10.1016/S1474-4422(09)70013-4. PubMed
  7. American College of Radiology. MRI Accreditation Program. acr.org
  8. American College of Radiology, American Association of Physicists in Medicine. ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance (MR) Imaging Equipment. acr.org
  9. American College of Radiology. ACR Manual on MR Safety. acr.org
  10. U.S. Food and Drug Administration. 21 CFR Part 892: Radiology Devices (Magnetic Resonance Diagnostic Device, 892.1000). ecfr.gov